Nilotinib based pharmacophore models for BCRABL.

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Tyrosine kinase inhibitors (TKIs) have transformed cancer treatment, particularly for chronic myeloid leukemia (CML).
• Imatinib resistance is a significant challenge in advanced CML, necessitating the development of alternative therapies.
• Nilotinib, a second-generation TKI, is more potent but also presents side effects.

Purpose of the Study:

• To identify novel natural compounds that can inhibit the BCR-ABL kinase, a driver of CML.
• To explore structure-based and ligand-based approaches for discovering new BCR-ABL inhibitors.
• To find potential drug-like molecules for treating imatinib-resistant CML.

Main Methods:

• Utilized pharmacophore modeling and molecular docking to screen natural compounds against the BCR-ABL kinase.
• Selected nilotinib as a reference pharmacophore due to its high binding efficiency.
• Docked 1457 natural compounds, filtering for those with shared pharmacophore features with nilotinib.

Main Results:

• Identified eleven natural compounds exhibiting pharmacophore similarity to nilotinib.
• Validated these compounds and performed docking studies to assess their potential as BCR-ABL inhibitors.
• Selected promising drug-like molecules from the screened candidates.

Conclusions:

• The identified natural compounds represent a potential novel class of BCR-ABL inhibitors.
• These compounds warrant further evaluation in cell lines for CML treatment.
• This study provides a foundation for developing new therapeutic strategies against resistant CML.